Results 1 to 10 of about 6,613 (165)
Comprehensive safety evaluation of Withania somnifera (Ashwagandha): an AI-driven meta-analysis and quantitative structure–activity relationship based toxicity assessment [PDF]
Frontiers in NutritionObjectiveThis study evaluates the safety profiles of Withania somnifera (Ashwagandha), an adaptogenic herb prevalent in Ayurvedic medicine, focusing on liver and reproductive toxicity.
Yotam Ronen +5 more
doaj +3 more sources
Effect of ashwagandha (Withania somnifera) on endocrine and reproductive traits in Awassi sheep [PDF]
Open Veterinary JournalBackground: Although ashwagandha, or Withania somnifera, is used as a broad-spectrum treatment to treat a wide range of illnesses, including reproductive issues, and to improve fertility, it is also considered a potent adaptogen and anti-stressor that ...
Ashraf Kamil Azeez +4 more
doaj +3 more sources
Pharmaceutics, 2023 In recent years, there has been a significant surge in reports on the health-promoting benefits of winter cherry (Withania somnifera), also known as Ashwagandha.
Magdalena Paczkowska +2 more
exaly +2 more sources
Pharmaceuticals, 2023 Herb-induced liver injury (HILI) caused by herbal supplements, natural products, and products used in traditional medicine are important for differential diagnoses in patients with acute liver injury without an obvious etiology.
Bojana Vidović +2 more
exaly +3 more sources
Plant Part–Specific Differences in Ashwagandha (Withania somnifera): A Comparative Evaluation of Root and Leaf Evidence for Safety and Regulation [PDF]
Food Sci NutrThis review contrasts the root and leaf of Withania somnifera (ashwagandha) across phytochemistry, clinical evidence, and regulatory context. Root preparations are dominated by withanolide A, D, and glyco‐withanolides, with multiple randomized controlled trials supporting reductions in stress, anxiety, and insomnia alongside a favorable safety profile.
Dutta A, Gupta J.
europepmc +2 more sources
Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review
Phytotherapy Research, Volume 40, Issue 8, Page 4792-4801, August 2026.The preclinical evidence for the safety of ashwagandha ( Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may ...
Elizabeth M. Williamson, T. Brendler
semanticscholar +2 more sources
Ashwagandha: Is It Safe? Part 1: A Regulatory Review
Phytotherapy Research, Volume 40, Issue 8, Page 4845-4857, August 2026.Over the last decade, ashwagandha ( Withania somnifera (L.) Dunal, AS) has been brought under increasing scrutiny by EU regulators regarding its safety for the use in food supplements, culminating in a recent recommendation for an Article 8 procedure ...
T. Brendler +5 more
semanticscholar +2 more sources
Phytotherapy Research, Volume 40, Issue 8, Page 4802-4812, August 2026.Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root
Jaising Salve +6 more
semanticscholar +2 more sources
Frontiers in NutritionAshwagandha or Withania somnifera is an herbal plant belonging to the Solanaceae family. Because of its wide range of phytochemicals, ashwagandha root extract has been used in numerous research studies, either alone or in conjunction with other natural ...
Shiyi Guo, Mohammad J. Rezaei
doaj +2 more sources
Treatment With Ashwagandha-Derived Exosome-Like Nanovesicles Up-Regulates VEGF-A Production and Promotes Human Hair Growth Ex Vivo. [PDF]
Exp DermatolABSTRACT Human‐derived exosomes show promise for hair loss treatment but may pose safety concerns, including inflammatory responses and pathogen transmission. Here, we investigated whether plant‐derived exosomes, whose isolation can be standardized, and which show lower compositional complexity and no immunogenicity, represent a valid alternative.
Le Riche A +12 more
europepmc +2 more sources